Trial of HQK-1001 in Beta Thalassemia Intermedia in Lebanon (LB-04-THAL)
|ClinicalTrials.gov Identifier: NCT01642758|
Recruitment Status : Completed
First Posted : July 17, 2012
Last Update Posted : March 14, 2013
Beta thalassemia intermedia syndromes are genetic anemias caused by mutations which reduce production of beta globin, a major component of adult hemoglobin A, the protein which delivers oxygen throughout the body. Patients suffer from poor growth, fatigue, heart failure, endocrine deficiencies, and eventually, many require chronic blood transfusions. There is no approved therapeutic for the deficiency of beta globin chains in beta thalassemia.
This trial will study an oral therapeutic which stimulates production of fetal globin, an alternate type which is produced by all humans, but is normally switched off in infancy. This type of globin can compensate for the missing protein in beta thalassemia.
|Condition or disease||Intervention/treatment||Phase|
|Beta Thalassemia Intermedia||Drug: Sodium 2,2 dimethylbutyrate||Phase 2|
This is a trial of an experimental oral medicine which stimulates production of fetal hemoglobin, an innate type of hemoglobin which is normally made but is suppressed in infancy. Fetal globin (HbF) can perform the function of the missing beta globin and reduce anemia in beta thalassemia, when it is produced in higher amounts than normal.
In this trial, 10 patients with beta thalassemia intermedia in Lebanon will all receive the study drug for 6 months at a dose which has been previously shown to be safe in normal volunteers and in beta thalassemia and sickle cell patients and to stimulate fetal globin production in many, when given for brief periods. The purpose of this trial is the following:
- To determine if total hemoglobin levels increase above baseline in some subjects when the study drug is taken for 26 weeks.
- To determine if fetal globin is increased above baseline levels in a proportion of subjects when the study drug is taken for 26 weeks.
- To determine the number of adverse events which occur with 26 weeks of administration of the study drug in beta thalassemia intermedia subjects.
After a screening period, the subjects will take the study drug at home once a day. They will be seen once every 4 weeks for examinations and laboratory tests during the dosing period and for 4 weeks afterwards.
This trial will provide an important step in evaluating a potential treatment for patients with beta thalassemia intermedia, that can be used around the world, if it is effective and safe.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-Label Phase 2 Study of HQK-1001 in Subjects With Beta Thalassemia Intermedia|
|Study Start Date :||May 2012|
|Actual Primary Completion Date :||November 2012|
|Actual Study Completion Date :||January 2013|
Experimental: Sodium 2,2 dimethylbutyrate
A single dose (20 mg/kg/day) of study drug will be taken once per day by mouth.
Drug: Sodium 2,2 dimethylbutyrate
Oral capsules, dose 20 mg/kg/day, once per day for 26 weeks
Other Name: ST20
- To measure changes from baseline in total hemoglobin when HQK-1001 is administered orally for 26 weeks in subjects with beta thalassemia intermedia. [ Time Frame: 6 months ]Baseline hemoglobin levels will be determined in each subject and averaged from levels obtained on a screening visit and on day one of the study, before any drug is taken. Hemoglobin levels will then be analyzed every 4 weeks during 26 weeks of taking the study drug and for 4 weeks after the dosing is completed. Changes from baseline will be determined.
- To measure the number of adverse events which occur with HQK-1001 treatment when given over 26 weeks in beta thalassemia intermedia. [ Time Frame: 6 months ]Adverse events which occur during HQK-1001 administration for 26 weeks will be recorded every 4 weeks.
- To measure changes from baseline in HbF during treatment with HQK-1001 for 26 weeks in beta thalassemia intermedia. [ Time Frame: 6 months ]Levels of HbF will be averaged from a screening visit and day 1 of the study, prior to any drug treatment. HbF levels will then be measured every 4 weeks during treatment and for 4 weeks after the treatment, and compared to each subject's baseline value. The number of subjects in which an increase in HbF develops above individuals' average baseline value will be obtained.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01642758
|Chronic Care Center|
|Study Director:||Susan P Perrine, MD||Boston University|
|Principal Investigator:||Adlette Inati, MD||Chronic Care Center and Rafik Hariri University Hospital, Beirut, Lebanon|